Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Promotes Global R&D VP Mackay To Head Unit, Opens Biotech Center

Executive Summary

Pfizer, as part of its ongoing efforts to reinvent its R&D model, is aiming to accelerate product development under a new leadership team and establish a significant presence in biotechnology with a new facility devoted to "bioinnovation.

You may also be interested in...



Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain

After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months

Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain

After completing a comprehensive review of its research program, Pfizer is rebuilding its late-stage pipeline, with plans to initiate Phase III studies for four new molecular entities and multiple new indications for existing drugs in the next 12 months

Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model

Following a strategic review of Bristol-Myers Squibb's business, the company's management unveiled a productivity initiative Dec. 5 designed to cut $1.5 billion in costs and fashion the drug maker into a "next-generation biopharma.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel